BullFrog AI Announces Issuance Of Australian Patent Protecting Novel Prodrugs Of Mebendazole And Their Use In Treating Cancer
Portfolio Pulse from Benzinga Newsdesk
BullFrog AI Holdings, Inc. announced the issuance of an Australian patent for novel prodrugs of mebendazole for cancer treatment. The compounds, including BF-223, show improved solubility and bioavailability, addressing challenges in using mebendazole for oncology. This follows a U.S. patent issued in July 2023 and positive preclinical study results for glioblastoma treatment. The company aims to monetize this asset with strategic partners.
January 16, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BullFrog AI has been granted an Australian patent for its novel prodrugs of mebendazole, aimed at treating cancer, which could enhance the company's intellectual property and commercial potential.
The issuance of the Australian patent for BullFrog AI's novel prodrugs of mebendazole is a significant step in protecting and commercializing the company's intellectual property. This development, coupled with the previous U.S. patent and positive preclinical results, could lead to increased investor confidence and potential strategic partnerships, which are likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100